ALXO
What one share of Alx Oncology Holdings holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. Our clinical pipeline includes two clinical-stage product candidates, the CD47 blocker evorpacept and an epidermal growth factor receptor (EGFR)-targeted antibody drug candidate (ADC) ALX2004.
Alx Oncology Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.93 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.82 |
| Cash and investments | $0.16 |
| Debt | $0.08 |
| Book value | $0.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.75 | −$6.33 | $0.24 | −$5.03 | — | −$18.82 |
| 2019 | $1.56 | −$7.56 | $0.11 | −$4.75 | — | −$22.31 |
| 2020 | $0.06 | −$2.76 | $0.00 | −$2.07 | — | — |
| 2021 | $0.00 | −$2.07 | $0.02 | −$1.71 | — | $8.94 |
| 2022 | $0.00 | −$3.03 | $0.04 | −$2.23 | — | $6.45 |
| 2023 | — | −$3.74 | $0.03 | −$3.06 | — | $3.80 |
| 2024 | — | −$2.58 | $0.01 | −$2.35 | — | $2.14 |
| 2025 | — | −$1.90 | $0.00 | −$1.57 | — | $0.48 |